{"id":10890,"date":"2024-11-02T14:23:17","date_gmt":"2024-11-02T06:23:17","guid":{"rendered":"https:\/\/flcube.com\/?p=10890"},"modified":"2024-11-03T20:53:32","modified_gmt":"2024-11-03T12:53:32","slug":"novartis-trispecific-antibody-pit565-secures-nmpa-approval-for-clinical-trial","status":"publish","type":"post","link":"https:\/\/flcube.com\/?p=10890","title":{"rendered":"Novartis’ Trispecific Antibody PIT565 Secures NMPA Approval for Clinical Trial"},"content":{"rendered":"\n

Swiss pharmaceutical giant Novartis (NYSE: NVS<\/a>) has received acceptance for its clinical trial application for the investigational drug PIT565 from the China National Medical Products Administration (NMPA). PIT565 is a potential “first-in-class” trispecific antibody targeting CD3, CD19, and CD2, which Novartis is developing to treat B-cell malignancies.<\/p>\n\n\n\n

Preclinical research results for PIT565 were published in the journal Blood in 2022. The robust expression of the CD19 antigen in acute lymphoblastic leukemia (ALL) and non-Hodgkin lymphoma (NHL) has driven the development of T cell redirecting therapies targeting CD19, including bispecific T cell engagers and CD19-targeting CAR-T therapies. However, T cell exhaustion often leads to treatment failure.<\/p>\n\n\n\n

To address this challenge, researchers have developed the IgG-like trispecific antibody PIT565, which targets CD19 on malignant B cells and engages both CD3 and CD2 on T cells, redirecting T cell cytotoxicity towards CD19-positive malignant B cells. Studies have shown that CD2 signaling is associated with a non-exhausted T cell phenotype. The interaction between CD2 and its ligand CD58 has been proven crucial for the efficacy of CD19 CAR-T cells in killing tumor cells, and the lack of CD58 expression on lymphoma cells is associated with resistance and relapse in patients treated with CD19 CAR-T therapy. Therefore, co-stimulation of CD2 by PIT565, compared to CD3 bispecifics, may overcome T cell exhaustion, increasing the depth and duration of patient responses.<\/p>\n\n\n\n

Preclinical studies have also indicated that PIT565 mediates more effective and sustained antitumor T cell responses compared to CD3 bispecifics, with greater T cell proliferation, cytokine production, and tumor cell lysis in vitro.<\/p>\n\n\n\n

Currently, PIT565 is being tested in an open-label, multicenter, Phase 1 study internationally to explore the preliminary efficacy and safety of the product in patients with relapsed or refractory B-NHL and R\/R CD19-positive B-ALL. The study involves dosing PIT565 either weekly (Q1W) or every two weeks (Q2W), with the route of administration (intravenous [IV] or subcutaneous [SC]) being explored during the dose-escalation phase. Patients initially receive PIT565 IV Q1W for a 28-day cycle, with the possibility of exploring Q2W treatment for 28-day cycles if preliminary pharmacokinetic (PK), pharmacodynamic, efficacy, and safety results are supportive.<\/p>\n\n\n\n

According to ClinicalTrials.gov, Novartis has also registered a Phase 1 clinical study to evaluate the safety, tolerability, and pharmacokinetics of PIT565 in patients with systemic lupus erythematosus (SLE), which has not yet begun recruiting participants.- Flcube.com<\/a><\/p>\n\n\n\n

<\/p>\n","protected":false},"excerpt":{"rendered":"

Swiss pharmaceutical giant Novartis (NYSE: NVS) has received acceptance for its clinical trial application for…<\/p>\n","protected":false},"author":1,"featured_media":10891,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"googlesitekit_rrm_CAownpewDA:productID":"","_jetpack_memberships_contains_paid_content":false,"footnotes":"","jetpack_publicize_message":"","jetpack_publicize_feature_enabled":true,"jetpack_social_post_already_shared":false,"jetpack_social_options":{"image_generator_settings":{"template":"highway","default_image_id":0,"font":"","enabled":false},"version":2}},"categories":[7,11],"tags":[16,21,62,140,865,25],"class_list":["post-10890","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-company","category-drug","tag-cancer","tag-car-t","tag-clinical-trial-approval-initiation","tag-novartis","tag-nyse-nvs","tag-potential-first-in-class"],"yoast_head":"\nNovartis' Trispecific Antibody PIT565 Secures NMPA Approval for Clinical Trial - Insight, China's Pharmaceutical Industry<\/title>\n<meta name=\"description\" content=\"Swiss pharmaceutical giant Novartis (NYSE: NVS) has received acceptance for its clinical trial application for the investigational drug PIT565 from the China National Medical Products Administration (NMPA). PIT565 is a potential "first-in-class" trispecific antibody targeting CD3, CD19, and CD2, which Novartis is developing to treat B-cell malignancies.\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/flcube.com\/?p=10890\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Novartis' Trispecific Antibody PIT565 Secures NMPA Approval for Clinical Trial\" \/>\n<meta property=\"og:description\" content=\"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM\" \/>\n<meta property=\"og:url\" content=\"https:\/\/flcube.com\/?p=10890\" \/>\n<meta property=\"og:site_name\" content=\"Insight, China's Pharmaceutical Industry\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/profile.php?id=61566606313834\" \/>\n<meta property=\"article:published_time\" content=\"2024-11-02T06:23:17+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2024-11-03T12:53:32+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/infoflow_2024-11-2_14-17-34.png\" \/>\n\t<meta property=\"og:image:width\" content=\"1457\" \/>\n\t<meta property=\"og:image:height\" content=\"663\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/png\" \/>\n<meta name=\"author\" content=\"Fineline Cube\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Fineline Cube\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"2 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=10890#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=10890\"},\"author\":{\"name\":\"Fineline Cube\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\"},\"headline\":\"Novartis’ Trispecific Antibody PIT565 Secures NMPA Approval for Clinical Trial\",\"datePublished\":\"2024-11-02T06:23:17+00:00\",\"dateModified\":\"2024-11-03T12:53:32+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=10890\"},\"wordCount\":405,\"commentCount\":0,\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=10890#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/infoflow_2024-11-2_14-17-34.png\",\"keywords\":[\"Cancer\",\"CAR-T\",\"Clinical trial approval \\\/ initiation\",\"Novartis\",\"NYSE: NVS\",\"Potential first-in-class\"],\"articleSection\":[\"Company\",\"Drug\"],\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"CommentAction\",\"name\":\"Comment\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=10890#respond\"]}],\"copyrightYear\":\"2024\",\"copyrightHolder\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"}},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=10890\",\"url\":\"https:\\\/\\\/flcube.com\\\/?p=10890\",\"name\":\"Novartis' Trispecific Antibody PIT565 Secures NMPA Approval for Clinical Trial - Insight, China's Pharmaceutical Industry\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=10890#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=10890#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/infoflow_2024-11-2_14-17-34.png\",\"datePublished\":\"2024-11-02T06:23:17+00:00\",\"dateModified\":\"2024-11-03T12:53:32+00:00\",\"description\":\"Swiss pharmaceutical giant Novartis (NYSE: NVS) has received acceptance for its clinical trial application for the investigational drug PIT565 from the China National Medical Products Administration (NMPA). PIT565 is a potential \\\"first-in-class\\\" trispecific antibody targeting CD3, CD19, and CD2, which Novartis is developing to treat B-cell malignancies.\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=10890#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=10890\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=10890#primaryimage\",\"url\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/infoflow_2024-11-2_14-17-34.png\",\"contentUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/infoflow_2024-11-2_14-17-34.png\",\"width\":1457,\"height\":663,\"caption\":\"Novartis' Trispecific Antibody PIT565 Secures NMPA Approval for Clinical Trial\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=10890#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/flcube.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Novartis’ Trispecific Antibody PIT565 Secures NMPA Approval for Clinical Trial\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"name\":\"Insight, China's Pharmaceutical Industry\",\"description\":\"Fineline Insights, Pharma Clarity\",\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/flcube.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\",\"name\":\"Fineline Infomation and Technology\",\"alternateName\":\"Fineline Info & Tech\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"contentUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"width\":2560,\"height\":1894,\"caption\":\"Fineline Infomation and Technology\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\"},\"sameAs\":[\"https:\\\/\\\/www.facebook.com\\\/profile.php?id=61566606313834\"]},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\",\"name\":\"Fineline Cube\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"caption\":\"Fineline Cube\"},\"sameAs\":[\"https:\\\/\\\/flcube.com\"],\"url\":\"https:\\\/\\\/flcube.com\\\/?author=1\"}]}<\/script>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"Novartis' Trispecific Antibody PIT565 Secures NMPA Approval for Clinical Trial - Insight, China's Pharmaceutical Industry","description":"Swiss pharmaceutical giant Novartis (NYSE: NVS) has received acceptance for its clinical trial application for the investigational drug PIT565 from the China National Medical Products Administration (NMPA). PIT565 is a potential \"first-in-class\" trispecific antibody targeting CD3, CD19, and CD2, which Novartis is developing to treat B-cell malignancies.","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/flcube.com\/?p=10890","og_locale":"en_US","og_type":"article","og_title":"Novartis' Trispecific Antibody PIT565 Secures NMPA Approval for Clinical Trial","og_description":"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM","og_url":"https:\/\/flcube.com\/?p=10890","og_site_name":"Insight, China's Pharmaceutical Industry","article_publisher":"https:\/\/www.facebook.com\/profile.php?id=61566606313834","article_published_time":"2024-11-02T06:23:17+00:00","article_modified_time":"2024-11-03T12:53:32+00:00","og_image":[{"width":1457,"height":663,"url":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/infoflow_2024-11-2_14-17-34.png","type":"image\/png"}],"author":"Fineline Cube","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Fineline Cube","Est. reading time":"2 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/flcube.com\/?p=10890#article","isPartOf":{"@id":"https:\/\/flcube.com\/?p=10890"},"author":{"name":"Fineline Cube","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a"},"headline":"Novartis’ Trispecific Antibody PIT565 Secures NMPA Approval for Clinical Trial","datePublished":"2024-11-02T06:23:17+00:00","dateModified":"2024-11-03T12:53:32+00:00","mainEntityOfPage":{"@id":"https:\/\/flcube.com\/?p=10890"},"wordCount":405,"commentCount":0,"publisher":{"@id":"https:\/\/flcube.com\/#organization"},"image":{"@id":"https:\/\/flcube.com\/?p=10890#primaryimage"},"thumbnailUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/infoflow_2024-11-2_14-17-34.png","keywords":["Cancer","CAR-T","Clinical trial approval \/ initiation","Novartis","NYSE: NVS","Potential first-in-class"],"articleSection":["Company","Drug"],"inLanguage":"en-US","potentialAction":[{"@type":"CommentAction","name":"Comment","target":["https:\/\/flcube.com\/?p=10890#respond"]}],"copyrightYear":"2024","copyrightHolder":{"@id":"https:\/\/flcube.com\/#organization"}},{"@type":"WebPage","@id":"https:\/\/flcube.com\/?p=10890","url":"https:\/\/flcube.com\/?p=10890","name":"Novartis' Trispecific Antibody PIT565 Secures NMPA Approval for Clinical Trial - Insight, China's Pharmaceutical Industry","isPartOf":{"@id":"https:\/\/flcube.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/flcube.com\/?p=10890#primaryimage"},"image":{"@id":"https:\/\/flcube.com\/?p=10890#primaryimage"},"thumbnailUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/infoflow_2024-11-2_14-17-34.png","datePublished":"2024-11-02T06:23:17+00:00","dateModified":"2024-11-03T12:53:32+00:00","description":"Swiss pharmaceutical giant Novartis (NYSE: NVS) has received acceptance for its clinical trial application for the investigational drug PIT565 from the China National Medical Products Administration (NMPA). PIT565 is a potential \"first-in-class\" trispecific antibody targeting CD3, CD19, and CD2, which Novartis is developing to treat B-cell malignancies.","breadcrumb":{"@id":"https:\/\/flcube.com\/?p=10890#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/flcube.com\/?p=10890"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/flcube.com\/?p=10890#primaryimage","url":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/infoflow_2024-11-2_14-17-34.png","contentUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/infoflow_2024-11-2_14-17-34.png","width":1457,"height":663,"caption":"Novartis' Trispecific Antibody PIT565 Secures NMPA Approval for Clinical Trial"},{"@type":"BreadcrumbList","@id":"https:\/\/flcube.com\/?p=10890#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/flcube.com\/"},{"@type":"ListItem","position":2,"name":"Novartis’ Trispecific Antibody PIT565 Secures NMPA Approval for Clinical Trial"}]},{"@type":"WebSite","@id":"https:\/\/flcube.com\/#website","url":"https:\/\/flcube.com\/","name":"Insight, China's Pharmaceutical Industry","description":"Fineline Insights, Pharma Clarity","publisher":{"@id":"https:\/\/flcube.com\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/flcube.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/flcube.com\/#organization","name":"Fineline Infomation and Technology","alternateName":"Fineline Info & Tech","url":"https:\/\/flcube.com\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/","url":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","contentUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","width":2560,"height":1894,"caption":"Fineline Infomation and Technology"},"image":{"@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/www.facebook.com\/profile.php?id=61566606313834"]},{"@type":"Person","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a","name":"Fineline Cube","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","caption":"Fineline Cube"},"sameAs":["https:\/\/flcube.com"],"url":"https:\/\/flcube.com\/?author=1"}]}},"jetpack_publicize_connections":[],"jetpack_featured_media_url":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/infoflow_2024-11-2_14-17-34.png","jetpack_sharing_enabled":true,"_links":{"self":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/10890","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=10890"}],"version-history":[{"count":1,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/10890\/revisions"}],"predecessor-version":[{"id":10892,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/10890\/revisions\/10892"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/media\/10891"}],"wp:attachment":[{"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=10890"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=10890"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=10890"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}